Jusmiral Holdings submits substantial acquisition disclosure for Cohance Lifesciences under SEBI takeover code

M&A / JV 30 Jun 2026 · In regulatory review· ✓ Verified

Jusmiral Holdings Limited has submitted a formal disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 to the NSE, signalling a substantial acquisition event in Cohance Lifesciences. This disclosure is mandatory when an acquirer crosses 25% threshold or intends material control acquisition. The filing initiates regulatory gating under the takeover code, requiring open offer mechanics, independent valuations, and adherence to pricing norms tied to the highest price paid in prior 52 weeks or volumetric average.

Why it mattersFiling of Reg 31(4) disclosure marks entry into the 90-day mandatory offer window; acquirer must now comply with open offer requirements, pricing benchmarks, and disclosure milestones-critical for deal closure and shareholder communication strategy.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals